Stocks › GILD
GILEAD SCIENCES, INC.
GILD·Nasdaq·
United States·USD
United States·USD$144.23
-0.40 (-0.28%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
GILD
GILEAD SCIENCES, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
GILDS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of GILD by members of U.S. Congress · 276 on record · 12 in the last 12 months
Whale Activity
Position changes in GILD reported for 2026-09-30 by 6 tracked institutional filers
- Increased0
- New0
- Held0
- Decreased1
- Closed0
- No prior filing5
| Filer | Shares | Value | Change |
|---|---|---|---|
| CONFLUENCE INVESTMENT MANAGEMENT LLC | 791.3K | $117.9M | — |
| CapWealth Advisors, LLC | 221.7K | $33.0M | — |
| First Financial Bank - Trust Division | 65.0K | $9.7M | — |
| Parrish Capital LLC | 18.4K | $2.7M | decreased |
| Defender Capital, LLC. | 1,500 | $224K | — |
| Sarver Vrooman Wealth Advisors | 613 | $91K | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by GILD insiders, by quarter · Form 4
Recent Insider Transactions
4,872 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| O'Day Daniel PatrickChairman & CEO · Director | Sale | −3,000 | $148.63 | $446K | Oct 1, 2026 | Form 4 ↗ |
| O'Day Daniel PatrickChairman & CEO · Director | Sale | −12.0K | $147.72 | $1.8M | Oct 1, 2026 | Form 4 ↗ |
| Mercier JohannaChief Comm & Corp Aff Officer | Sale | −800 | $144.46 | $116K | Sep 15, 2026 | Form 4 ↗ |
| Mercier JohannaChief Comm & Corp Aff Officer | Sale | −600 | $145.29 | $87K | Sep 15, 2026 | Form 4 ↗ |
| Mercier JohannaChief Comm & Corp Aff Officer | Sale | −1,600 | $143.69 | $230K | Sep 15, 2026 | Form 4 ↗ |
| Dickinson Andrew DChief Financial Officer | Sale | −3,000 | $145.29 | $436K | Sep 15, 2026 | Form 4 ↗ |
| O'Day Daniel PatrickChairman & CEO · Director | Sale | −7,992 | $148.36 | $1.2M | Sep 1, 2026 | Form 4 ↗ |
| O'Day Daniel PatrickChairman & CEO · Director | Sale | −5,408 | $149.38 | $808K | Sep 1, 2026 | Form 4 ↗ |
| O'Day Daniel PatrickChairman & CEO · Director | Sale | −1,600 | $147.51 | $236K | Sep 1, 2026 | Form 4 ↗ |
| WELTERS ANTHONYDirector · Director | Sale | −6,880 | $148.82 | $1.0M | Aug 26, 2026 | Form 4 ↗ |
| WELTERS ANTHONYDirector · Director | Sale | −4,600 | $148.82 | $685K | Aug 26, 2026 | Form 4 ↗ |
| WELTERS ANTHONYDirector · Director | Sale | −3,402 | $148.24 | $504K | Aug 26, 2026 | Form 4 ↗ |
| WELTERS ANTHONYDirector · Director | Sale | −3,118 | $148.31 | $462K | Aug 26, 2026 | Form 4 ↗ |
| Bluestone JeffreyDirector · Director | Sale | −335 | $146.26 | $49K | Aug 20, 2026 | Form 4 ↗ |
| Bluestone JeffreyDirector · Director | Sale | −26 | $146.36 | $4K | Aug 20, 2026 | Form 4 ↗ |
| Bluestone JeffreyDirector · Director | Sale | −1,816 | $144.92 | $263K | Aug 20, 2026 | Form 4 ↗ |
| Bluestone JeffreyDirector · Director | Sale | −1,658 | $145.73 | $242K | Aug 20, 2026 | Form 4 ↗ |
| Bluestone JeffreyDirector · Director | Sale | −1,165 | $143.75 | $167K | Aug 20, 2026 | Form 4 ↗ |
| Mercier JohannaChief Comm & Corp Aff Officer | Sale | −16.5K | $137.37 | $2.3M | Aug 17, 2026 | Form 4 ↗ |
| Mercier JohannaChief Comm & Corp Aff Officer | Sale | −11.5K | $138.04 | $1.6M | Aug 17, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding GILD · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 39.4M | $4.98B | 0.22% | Jun 30, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 32.2M | $4.06B | 0.24% | Jun 30, 2026 |
| Invesco QQQ Trust, Series 1 | 26.4M | $3.33B | 0.68% | Jun 30, 2026 |
| Dodge & Cox Stock Fund Dodge & Cox Funds | 17.3M | $2.18B | 1.84% | Jun 30, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 17.1M | $2.16B | 0.24% | Jun 30, 2026 |
| Fidelity 500 Index Fund Fidelity Concord Street Trust | 15.9M | $2.13B | 0.26% | May 31, 2026 |
| Income Fund of America | 15.5M | $2.02B | 1.36% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust | 15.0M | $1.90B | 0.24% | Jun 30, 2026 |
| VANGUARD VALUE INDEX FUND VANGUARD INDEX FUNDS | 11.8M | $1.49B | 0.59% | Jun 30, 2026 |
| Fidelity Contrafund | 11.4M | $1.44B | 0.80% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list GILD's shares (CUSIP 375558103), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
No 13D/13G beneficial-ownership filings on record.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming gilead sciences as client
- TARPLIN, DOWNS & YOUNG, LLCGILEAD SCIENCES, INC. · 2026 Q2 · BUD, HCR, MMM$80K
Filing ↗ - TODD STRATEGY GROUPGILEAD SCIENCES, INC. · 2026 Q2 · HCR$80K
Filing ↗ - FORBES-TATEGILEAD SCIENCES, INC. · 2026 Q2 · HCR$90K
Filing ↗ - GILEAD SCIENCES, INC.GILEAD SCIENCES INC · 2026 Q2 · CPT, BUD, TAX, TRD$1.6M
Filing ↗ - W STRATEGIES, LLCGILEAD SCIENCES, INC. · 2026 Q2 · MMM$60K
Filing ↗
Government Contracts
Federal awards to GILEAD SCIENCES, INC. · USAspending
No federal contract awards found for GILEAD SCIENCES, INC..
U.S. Patents
Recent USPTO applications naming GILEAD SCIENCES, INC.
No USPTO patent applications found for GILEAD SCIENCES, INC..
Annual Financials
From GILD's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $29.44B | $28.75B | $27.12B | $27.28B | $27.30B |
| Operating income | $10.02B | $1.66B | $7.61B | $7.33B | $9.92B |
| Net income | $8.51B | $480.0M | $5.67B | $4.59B | $6.22B |
| Diluted EPS | $6.78 | $0.38 | $4.50 | $3.64 | $4.93 |
| Operating cash flow | $10.02B | $10.83B | $8.01B | $9.07B | $11.38B |
| Cash and equivalents | n/a | n/a | n/a | $5.41B | $5.34B |
| Total assets | $59.02B | $58.99B | $62.13B | $63.17B | $67.95B |
| Shareholders' equity | $22.70B | $19.33B | $22.83B | $21.24B | $21.07B |
As GILEAD SCIENCES, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 24, 2026 ↗
Stock Splits
Every split and reverse split in the price history
- 2-for-1Stock splitJan 28, 2013
- 2-for-1Stock splitJun 25, 2007
- 2-for-1Stock splitSep 7, 2004
- 2-for-1Stock splitMar 8, 2002
- 2-for-1Stock splitFeb 22, 2001
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 9.01Results of operationsAug 4, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.03, 8.01, 9.01Material agreement · Direct financial obligation · Other eventsMay 20, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 7, 2026
EDGAR ↗ - 8-K · Items 5.07, 9.01Shareholder voteMay 4, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsApr 28, 2026
EDGAR ↗ - 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureFeb 23, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsFeb 10, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeNov 19, 2025
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsOct 30, 2025
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureOct 6, 2025
EDGAR ↗
About GILEAD SCIENCES, INC.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersFOSTER CITY, CA
IncorporatedDE
SEC CIK0000882095 ↗
Former namesGILEAD SCIENCES INC